AL Amyloidosis: Clinical Trials

6 trials for AL Amyloidosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 completed, 1 recruiting, 1 terminated. 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 36Active not recruiting 2, Completed 2, Recruiting 1, Terminated 1

Follow AL Amyloidosis: new trials by email Literature Review of AL Amyloidosis trials Research Report on AL Amyloidosis

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection - AL Amyloidosis
Phase 3RecruitingSWOG Cancer Research Network3382024-07-012026-05-06
Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
[18F]florbetaben - Cardiac Amyloidosis, AL Amyloidosis
Phase 3CompletedLantheus Germany GmbH2442023-01-132026-10-26
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
CAEL-101, Placebo, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen - AL Amyloidosis
Phase 3Active not recruitingAlexion Pharmaceuticals, Inc.2812020-11-032026-06-17
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen - AL Amyloidosis
Phase 3Active not recruitingAlexion Pharmaceuticals, Inc.1252020-08-252026-07-02
Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib
Bortezomib, Melphalan, Neupogen - AL Amyloidosis
Phase 3TerminatedBoston Medical Center32015-06-012018-09-10
A Trial for Systemic Light-chain (AL) Amyloidosis
BMDex - AL Amyloidosis
Phase 3CompletedEuropean Myeloma Network B.V.1102011-01-012017-03-10

Narrower conditions

Immunoglobulin Light-chain Amyloidosis (6)  ·  Paraproteinemias (2)  ·  Amyloid Neuropathies, Familial (1)  ·  Amyloidosis (1)

Broader conditions

Immune System Diseases (6)  ·  Immunoproliferative Disorders (6)  ·  Lymphoproliferative Disorders (6)  ·  Metabolic Diseases (6)  ·  Neoplasms (6)  ·  Neoplasms by Histologic Type (6)  ·  Neoplasms, Plasma Cell (6)  ·  Nutritional and Metabolic Diseases (6)  ·  Proteostasis Deficiencies (6)  ·  Amyloidosis (5)  ·  Paraproteinemias (4)  ·  Blood Protein Disorders (2)  ·  Hematologic Diseases (2)  ·  Hemic and Lymphatic Diseases (2)  ·  Amyloid Neuropathies (1)

Interventions

Bortezomib (4)  ·  Cyclophosphamide (3)  ·  Dexamethasone (3)  ·  Melphalan (3)  ·  Clinical Protocols (2)  ·  4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1)  ·  Biopsy (1)  ·  Blood Component Removal (1)  ·  Calcium Dobesilate (1)  ·  Filgrastim (1)  ·  Granulocyte Colony-Stimulating Factor (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Specimen Handling (1)  ·  Stem Cell Transplantation (1)  ·  auricularum (1)

Sponsors

Alexion Pharmaceuticals, Inc. (2)  ·  Boston Medical Center (1)  ·  European Myeloma Network B.V. (1)  ·  Lantheus Germany GmbH (1)  ·  SWOG Cancer Research Network (1)

Countries

United States (5)  ·  Germany (3)  ·  Italy (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  Australia (2)  ·  Austria (2)  ·  Belgium (2)  ·  Brazil (2)  ·  Canada (2)  ·  China (2)  ·  Czechia (2)  ·  France (2)  ·  Greece (2)  ·  Israel (2)

Top investigators

Scott Swenson, MD (2)  ·  Andrew Stephens, MD, PhD (1)  ·  Patrick A Hagen (1)  ·  Vaishali Sanchorawala, MD (1)

Results publications

PMID 42212672, PMID 20085941, PMID 32730181

NIH funding

U10CA180888 (1)